Phaseline

Targets › HTR6

HTR6 (5-hydroxytryptamine receptor 6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Dec 2026.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen. Also has a high affinity for tricyclic psychotropic drugs (By similarity). (UniProt, P50406)

Open in Phaseline: the race on HTR6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Suven Life SciencesMasupirdine (SUVN-502)
Serotonin 6 (5-HT6) receptor antagonist
HTR6Phase 3AgitationDec 2026

Conditions

Agitation (1)

Modalities

small molecule (1)

Companies

Suven Life Sciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.